# A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253

> **NCT01697501** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 88 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **OTHER:** Interleukin 28B testing

## Key facts

- **NCT ID:** NCT01697501
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-08
- **Primary completion:** 2013-06-21
- **Final completion:** 2013-06-21
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697501, "A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01697501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*